Enantioselective reduction of pentoxifylline to lisofylline using whole‐cell Lactobacillus kefiri biotransformation

Biotechnology Journal - Tập 2 Số 4 - Trang 492-496 - 2007
Elżbieta Pękala1, Anna Godawska‐Matysik1, Dorota Żelaszczyk1
1Jagiellonian University, Medical College, Department of Technology and Biotechnology of Drugs, Cracow, Poland

Tóm tắt

AbstractLisofylline (LSF) is a drug candidate that has been under investigation for acute respiratory distress syndrome, acute lung injury, septic shock and mucositis. As LSF is not commercially available in our country, we produced it for pharmacokinetic studies. In the present work whole‐cell reduction of pentoxifylline [1‐(5‐oxohexyl)‐3,5‐dimethylxanthine] to LSF [1‐(5R‐hydroxyhexyl)‐3,5‐dimethylxanthine] using Lactobacillus kefiri DSM 20587 was investigated. Glucose or 2‐propanol was used as a co‐substrate to regenerate the NADPH cofactor. The reaction conditions were optimized. The influence of different concentrations of co‐substrates on the yield and enantioselectivity of the biotransformation of pentoxifylline into LSF were tested. Maximum yield (100%) of biotransformation was reached in the presence of glucose as a co‐substrate. At glucose concentrations of 675 and 900 mM the bioreduction of pentoxifylline proceeded highly enantioselectively (enantiomeric excess for the R enantiomer of 98%).

Từ khóa


Tài liệu tham khảo

10.1002/chir.10129

10.1016/S0958-1669(01)00266-X

10.1016/S0040-4020(01)01009-2

10.1016/j.cbpa.2004.02.005

10.1002/tcr.20016

Kula M.‐T. Dehydrogenases in the synthesis of chiral compounds in: Patel R. N. (Ed.) Stereoselective Biocatalysis Dekker New York 2002 pp. 839‐866.

10.1111/j.1574-6968.1990.tb03775.x

10.1007/s00253-003-1347-y

10.1038/35051736

10.1002/anie.198405701

10.1351/pac196409010119

10.1111/j.1749-6632.1987.tb45698.x

10.1002/anie.198401511

10.1016/S0957-4166(03)00526-3

10.1021/ja00261a026

10.1007/BF00170916

10.1021/jo00031a037

10.1007/s00253-002-0936-5

10.1007/s00253-004-1765-5

10.1007/s00253-005-1921-6

10.1007/s00253-004-1837-6

10.1016/j.tetasy.2005.01.013

10.1007/s00253-005-0168-6

10.1007/BF01024393

10.1016/j.tetasy.2006.06.033

10.1080/10242420600893827

10.1016/j.cbpa.2004.02.005

van der Donk W. A., 2003, Regeneration of cofactors for use in biocatalysis., Curr. Opin. Biotechnol., 14, 583, 10.1016/j.copbio.2003.09.007

Lillibridge J. A., 1996, Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol., Drug Met. Dispos., 24, 1174

10.1084/jem.181.2.569

Wong J. S., 1996, Lisofylline as a modifier of radiation therapy., Oncol. Res., 8, 513

10.1016/j.bcp.2004.08.012

Bianco J. A. Woodson P. Parubek D. Singer J. (Cell Therapeut. Inc.) Enantiomeric hydroxylated xanthine cpds. JP 94509584 JP 96259565 WO 9317684.

Klein J. P. Leigh A. J. Michnick J. Kumar A. M. Underiner G. E. (Cell Therapeut. Inc.) Asymmetric synthesis of chiral secondary alcohols. DE 9531450.

Aretz W. Furrer H. Gebert U. Hinze H.‐J. (Hoechst AG) Process for the enantoselective preparation of (ω‐1)‐hydroxyalkyl xanthines. DE 3942872.

Pękala E. Wójcik T. Enantioselective biotransformation of pentoxifylline into lisofylline using wine yeast biocatalysis.Acta Polon. Pharmac. Drug Res.in press 5 2007.

10.1002/chir.20299

Thông tin
Thông tin xuất bản

Biotechnology Journal

Tập 2 Số 4

492-496

Thông tin tác giả